Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
https://www.fool.com/investing/2024/03/13/does-this-1-new-threat-make-sarepta-therapeutics/?source=iedfolrf0000001
Mar 13, 2024 - The threat is still emerging, but it could be significant.
0
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
https://www.fool.com/investing/2023/12/22/could-sarepta-therapeutics-be-the-next-vertex/?source=iedfolrf0000001
Dec 22, 2023 - Both develop medicines for rare diseases, and each aims to conquer a niche market.
0
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/29/sarepta-therapeutics-srpt-q4-2023-earnings-call-tr/?source=iedfolrf0000001
Feb 28, 2024 - SRPT earnings call for the period ending December 31, 2023.
0
Wall Street Analysts See a 53.71% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2198730/wall-street-analysts-see-a-53-71-upside-in-sarepta-therapeutics-srpt-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2198730
Dec 15, 2023 - The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Sarepta Therapeutics (SRPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
0
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
https://www.zacks.com/stock/news/2208400/sellas-sls-rises-on-fda-fast-track-tag-to-leukemia-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208400
Jan 10, 2024 - The FDA bestows a Fast Track Designation to SELLAS' (SLS) pipeline candidate, SLS009, for the treatment of relapsed/refractory acute myeloid leukemia. Stock gains.
0
Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine
https://www.zacks.com/stock/news/2209718/emergent-ebs-gets-235-8m-dod-contract-for-anthrax-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209718
Jan 12, 2024 - Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.
0
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
https://www.zacks.com/stock/news/2211622/vertex-vrtx-crsp-s-casgevy-gets-fda-nod-for-thalassemia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2211622
Jan 17, 2024 - This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
0
TransCode (RNAZ) Down 50% on Issue of New Common Stock
https://www.zacks.com/stock/news/2213010/transcode-rnaz-down-50-on-issue-of-new-common-stock?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213010
Jan 19, 2024 - TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
0
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
https://www.zacks.com/stock/news/2213712/edgewise-ewtx-rallies-35-on-issue-of-new-common-stock?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2213712
Jan 22, 2024 - Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
0
What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings?
https://www.zacks.com/stock/news/2213563/what-s-in-store-for-zimmer-biomet-zbh-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2213563
Jan 22, 2024 - Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.
0
Page 1>